The study, REDEFINE 3, is looking at a combination of two medicines. REDEFINE 3 is needed to help us understand how effective these two medicines are for reducing cardiovascular events, such as heart attacks and stroke. This study is funded and sponsored by Novo Nordisk. 

This study is open at PRC: Bradford, PRC: Leicester, PRC: Exeter. And upcoming at PRC: Blackpool and PRC: Newcastle.

The purpose of this study is to characterise the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of Atherosclerotic Cardiovascular Diseases (ASCVD) as defined by their medical history and is 2-fold:
- Evaluate the distribution of Lp(a) value in the overall participants with a documented history of ASCVD
- Evaluate the distribution of Lp(a) value in participants with a documented history of ASCVD by demographics and regions.

This study is evaluating the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for participants with HER2-positive breast cancer at high risk of recurrence following preoperative therapy.

The ExPEC study is assessing the efficacy, safety and immunogenicity of vaccination with ExPEC9V which is used as a preventative treatment of invasive extraintestinal pathogenic Escherichia Coli disease in adults aged 60-years and older with a history of urinary tract infection in the past two years. It is a randomised, double-blind, placebo-controlled, multi-centre phase 3 study.

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalisation for heart failure or need for outpatient intravenous (IV) diuretics.

This phase 3 randomised study will compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma.

The study will be conducted in 3 phases: Screening Phase, Treatment Phase, and Follow-up Phase. Participants will be treated until disease progression, unacceptable toxicity , or other reasons to discontinue the study.

This phase 3, double-blind, randomised study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

This multi-centre, randomised, observer-blind, active-controlled, superiority study in adults to compares the immunogenicity of Valneva’s VLA2001 COVID-19 vaccine candidate, against the AstraZeneca AZD1222 (ChAdOx1-S) vaccine. VLA2001 will also be compared to placebo in an adolescent population.

The DAPA-MI study is evaluating if dapagliflozin (a drug developed to treat diabetes) can also be effective in reducing the risk of heart failure and death following a heart attack. This is a multicentre, parallel group, event-driven, registry-based randomised controlled trial (R-RCT), double-blind, placebo-controlled phase 3 study. Dapagliflozin, which is given once daily in addition to Standard of Care therapy, will be evaluated versus placebo for the prevention of hospitalisation for heart failure or cardiovascular death.

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalisation and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has an impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. This clinical trial is a multi-centre, randomised, double-blind, parallel-group, placebo-controlled study.